News | June 21, 2012

Biosensors Announces First Large-Scale Study with BioFreedom

June 21, 2012 — Plans for a new study involving BioFreedom, the polymer-free drug-coated stent (DCS) from Biosensors, were announced  at EuroPCR by principal investigator Dr. Philip Urban, Hôpital de la Tour, Geneva.  

Leaders Free is the world’s first prospective, randomized double-blind trial between a DCS and bare-metal stent (BMS), assessing the potential to deliver the anti-restenotic benefit of a drug-eluting stent with a shorter course of dual anti-platelet therapy (DAPT) in patients at high risk of bleeding. 

Leaders Free will enroll approximately 2,500 patients from 60 sites across Europe, Asia and South America, with follow-up for two years. The trial will include patients identified as having a high risk of bleeding. Patients in both arms of the study will be prescribed only one month of DAPT, although they will take a single anti-platelet drug indefinitely. 

The co-primary endpoints of the study will be: 1) non-inferiority of BioFreedom compared with BMS in terms of specific safety factors (cardiac death, myocardial infarction, and definite/probable stent thrombosis) after one year and; 2) superiority over BMS in terms of clinically-driven target lesion revascularization (TLR) at 12 months.

Investigators anticipate enrolling the first patient within the next few months, and completing the process by early 2014. Primary endpoint data is likely to be presented during 2015.

BioFreedom represents development in Biosensors’ stent technology, featuring a micro-structured abluminal surface which permits the controlled release of Biolimus A9 (BA9) without the use of a polymer. BA9 is a highly lipophilic anti-restenotic drug developed by Biosensors specifically for use with stents.

Biosensors has applied for CE mark approval for BioFreedom. As with its other products, the company is committed to building a significant body of clinical evidence before making BioFreedom commercially available. Leaders Free will represent a major contribution to the evidence surrounding the use of BioFreedom in patients at high risk of bleeding. 

For more information: www.biosensors.com

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init